Cargando…

Deep multiomics profiling of brain tumors identifies signaling networks downstream of cancer driver genes

High throughput omics approaches provide an unprecedented opportunity for dissecting molecular mechanisms in cancer biology. Here we present deep profiling of whole proteome, phosphoproteome and transcriptome in two high-grade glioma (HGG) mouse models driven by mutated RTK oncogenes, PDGFRA and NTR...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hong, Diaz, Alexander K., Shaw, Timothy I., Li, Yuxin, Niu, Mingming, Cho, Ji-Hoon, Paugh, Barbara S., Zhang, Yang, Sifford, Jeffrey, Bai, Bing, Wu, Zhiping, Tan, Haiyan, Zhou, Suiping, Hover, Laura D., Tillman, Heather S., Shirinifard, Abbas, Thiagarajan, Suresh, Sablauer, Andras, Pagala, Vishwajeeth, High, Anthony A., Wang, Xusheng, Li, Chunliang, Baker, Suzanne J., Peng, Junmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697699/
https://www.ncbi.nlm.nih.gov/pubmed/31420543
http://dx.doi.org/10.1038/s41467-019-11661-4
Descripción
Sumario:High throughput omics approaches provide an unprecedented opportunity for dissecting molecular mechanisms in cancer biology. Here we present deep profiling of whole proteome, phosphoproteome and transcriptome in two high-grade glioma (HGG) mouse models driven by mutated RTK oncogenes, PDGFRA and NTRK1, analyzing 13,860 proteins and 30,431 phosphosites by mass spectrometry. Systems biology approaches identify numerous master regulators, including 41 kinases and 23 transcription factors. Pathway activity computation and mouse survival indicate the NTRK1 mutation induces a higher activation of AKT downstream targets including MYC and JUN, drives a positive feedback loop to up-regulate multiple other RTKs, and confers higher oncogenic potency than the PDGFRA mutation. A mini-gRNA library CRISPR-Cas9 validation screening shows 56% of tested master regulators are important for the viability of NTRK-driven HGG cells, including TFs (Myc and Jun) and metabolic kinases (AMPKa1 and AMPKa2), confirming the validity of the multiomics integrative approaches, and providing novel tumor vulnerabilities.